Yohann Loriot

Yohann Loriot, MD, PhD is a medical oncologist and principal investigator at Institut Gustave Roussy (IGR) in Villejuif, France, one of Europe's foremost cancer centers. He has built a distinguished career focused on the biology and treatment of urothelial carcinoma, with particular expertise in molecularly targeted therapies for bladder cancer. His work bridges deep translational science and landmark clinical trials, making him one of the most influential European voices in genitourinary oncology. Dr. Loriot is internationally recognized as the lead investigator of the BLC2001 trial, a pivotal phase II study evaluating erdafitinib—a pan-FGFR kinase inhibitor—in patients with metastatic urothelial carcinoma harboring FGFR2 or FGFR3 gene alterations. This trial, published in the New England Journal of Medicine in 2019, demonstrated remarkable response rates in this biomarker-selected population and led directly to the FDA approval of erdafitinib as the first targeted therapy in urothelial carcinoma and the first FGFR inhibitor approved in any solid tumor. BLC2001 is considered a landmark example of genotype-matched therapy in bladder cancer. Dr. Loriot has also contributed extensively to the development of antibody-drug conjugates, immunotherapy strategies, and novel combinations in urothelial carcinoma at IGR. He is an active collaborator in ESMO guideline development, a prolific author with more than 200 peer-reviewed publications, and a member of the European Association of Urology (EAU) guidelines panel. His translational research into FGFR pathway biology continues to generate insights into resistance mechanisms and combination strategies.